ImmunOs Therapeutics AG, the leader in discovery and development of next generation, novel immunotherapeutics
Immunos Therapeutics AG is leading the next generation of immunotherapies for cancer by developing therapies that have a role in the innate immune system which not only have direct anti-tumor effects but also remodel the tumor microenvironment to enhance the efficacy of existing immunotherapies and improve patient lives.
This industry leading portfolio of next generation, novel immunomodulatory proteins target diverse and key immunoregulatory receptors and exhibit strong anti-tumor responses in multiple cancers with monotherapy and in combination with checkpoint inhibitors (CTLA-4, PD-1, PD-L1) and costimulatory agonists (e.g. 4-1BB).
Immune system prevents cancer development through its natural ability to detect and destroy abnormal cells. However, cancer cells may avoid this detection system and start growing without control.
Immunotherapy is widely recognized as a revolutionary breakthrough by using agents which stimulate the immune system to recognize and destroy cancer cells. Various Immuno-Oncology (IO) Treatment Modalities have been developed and new approaches are being explored. Checkpoint inhibitors (PD-1, PD-L1, and CTLA-4), which block immunosuppressive signals from tumors, are becoming the foundation immunotherapy agents.
Both the adaptive and innate arms of the immune system play a key role in tumor development or suppression. The innate immune system can recognize pathogens and damaged tissue and can rapidly identify and attack tumor cells. Different cell components constitute the innate immune system, where the principal cell types playing key roles in cancer immunosurveillance are Macrophages, Myeloid Derived Suppressor cells (MDSCs), Natural killer cells (NK cells) and Dendritic cells. The adaptive immune system is ‘antigen-specific’ and it generates a more methodical, tumor-specific response; Cytotoxic T cells are the main cells of the adaptive immune system.
Current approaches focus mainly on stimulating the adaptive immune system and more specifically cytotoxic T cells – either by generating new T cells through vaccines, CAR-T cell therapies or by blocking immunosuppressive signals that prevent T cells from doing their job (checkpoint inhibitors). Efficacy is limited to selected tumors and they benefit only a subset of cancer patients in these tumors (5 to 40% responders). Experts envision that combination therapy is necessary to improve the results of these first-generation immunotherapies. The evolving science has revealed that there are many factors in the tumor microenvironment, the area directly surrounding the tumor, which block the ability of the immune system to do its job. Scientists believe that the therapies which will lead the way in Immuno-Oncology 2.0 will be the agents that can remodel the tumor microenvironment, making the tumor vulnerable to immunotherapy.
ImmunOs is developing the next generation of immunotherapies for cancer treatment. These therapies have demonstrated improved immunotherapy efficacy and survival rates in preclinical cancer models across diverse cancer indications.
ImmunOs products target diverse and key immunoregulatory receptors (multi-targeting approach while activating strong anti-tumor response), while most antibodies only target a single receptor. The impact of this multi-targeting approach is a remodeling of the tumor microenvironment which allows immunotherapy to work. This remodeling of the TME occurs in a few different ways: First, Immunos products stimulate the innate immune system directly by activating M1-type Macrophages and suppressing M2-type Macrophages. Shifting from the M2 to M1-type TME is vital as the M1-type facilitates a robust immune response to tumors. Second, ImmunOs products block immuno-suppressive MDSCs cells, allowing the expansion of killer CD8+ T cells, which can directly destroy cancer. In addition to remodeling the TME, ImmunOs products directly stimulate NK-cells which can have a strong anti-tumor effect. Because our molecules make the environment more amenable to immunotherapy, we have demonstrated strong anti-tumor responses in combination with checkpoint inhibitors such as (CTLA-4, PD-1, PD-L1 and agonist antibodies such as 4-1BB) in multiple cancer indications.
Lymphocytes trying to eliminate tumor cell
ImmunOs Therapeutics Targets